Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZW) Cash from Financing Activities (2021 - 2025)

Core Scientific (CORZW) has disclosed Cash from Financing Activities for 5 consecutive years, with -$21.8 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 103.65% to -$21.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$63.1 million through Dec 2025, down 107.7% year-over-year, with the annual reading at -$63.1 million for FY2025, 107.7% down from the prior year.
  • Cash from Financing Activities hit -$21.8 million in Q4 2025 for Core Scientific, down from -$5.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $598.2 million in Q4 2024 to a low of -$45.1 million in Q3 2022.
  • Historically, Cash from Financing Activities has averaged $81.1 million across 5 years, with a median of $10.0 million in 2021.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 148.04% in 2023 and later skyrocketed 5424.49% in 2024.
  • Year by year, Cash from Financing Activities stood at $170.2 million in 2021, then plummeted by 77.63% to $38.1 million in 2022, then tumbled by 148.04% to -$18.3 million in 2023, then soared by 3369.23% to $598.2 million in 2024, then plummeted by 103.65% to -$21.8 million in 2025.
  • Business Quant data shows Cash from Financing Activities for CORZW at -$21.8 million in Q4 2025, -$5.3 million in Q3 2025, and -$31.8 million in Q2 2025.